Pacira Pharmaceuticals (PCRX) Earns Daily Media Impact Rating of 0.17

News coverage about Pacira Pharmaceuticals (NASDAQ:PCRX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.2026958759254 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $44.20 on Friday. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a 1-year low of $29.81 and a 1-year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 earnings per share. sell-side analysts anticipate that Pacira Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

PCRX has been the topic of several research analyst reports. Mizuho downgraded Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $53.00 to $44.00 in a research note on Wednesday, November 29th. Canaccord Genuity set a $42.00 price objective on Pacira Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 29th. BMO Capital Markets lifted their price target on Pacira Pharmaceuticals from $38.00 to $39.00 and gave the company a “market perform” rating in a research note on Wednesday, November 8th. Jefferies Group dropped their price target on Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $48.86.

In other news, CAO Kristen Marie Williams sold 10,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 23,455 shares in the company, valued at $938,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David M. Stack sold 58,885 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the transaction, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,735 shares of company stock valued at $2,692,594. Company insiders own 6.60% of the company’s stock.

WARNING: “Pacira Pharmaceuticals (PCRX) Earns Daily Media Impact Rating of 0.17” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-pacira-pharmaceuticals-pcrx-stock-price.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply